In a phase 2 trial, nivolumab achieved a response rate of 58% in patients with mismatch-repair-deficient gynecological cancers, meeting the primary endpoint, and genomic and immunologic features correlated with response.
- Claire F. Friedman
- Beryl L. Manning-Geist
- Dmitriy Zamarin
